HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xiao, H. Articles by Isobe, K.-i. Search for Related Content PubMed PubMed Citation Articles by Xiao, H. Articles by Isobe, K.-i. Social Bookmarking                      What's this?

J Biol Chem, Vol. 275, Issue 2, 1371-1376, January 14, 2000

p300 Collaborates with Sp1 and Sp3 in p21^waf1/cip1 Promoter Activation Induced by Histone Deacetylase Inhibitor^*

Hengyi Xiao^§¶, Tadao Hasegawa, and Ken-ichi Isobe

From the  Department of Basic Gerontology, National Institute for Longevity Sciences, 36-3, Gengo Morioka-Cho, Obu, Aichi, 474-8522 Japan and the ^§ Institute of Cancer Research, West China University of Medical Sciences, Chengdu, Sichuan, 610041 People's Republic of China

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

We have reported that histone acetylation induced by trichostatin A (TSA) promotes p21^waf1/cip1 (p21) expression, the GC-box located just upstream of TATA box was responsible for TSA-induced promoter activation, and both Sp1 and Sp3 were the working activator of this GC-box. To understand the molecular pathway from histone acetylation to this Sp1 family factors-mediated promoter activation, we investigated the function of p300, one of the histone acetyltransferase, in the present work. The evidence supporting the linkage between p300 and TSA-induced p21 promoter activation were realized from the following findings: 1) cotransfection of p300 elevated p21 promoter activity, and this elevation was dependent on TSA-responsive GC-box; 2) TSA-induced promoter activation was blocked by the introduction of p300 dominant-negative mutant into cells; and 3) Sp1- or Sp3-mediated activation was also suppressed by this p300 dominant-negative mutant. Our data also suggested that p300 collaborates with Sp1 in a way which is different from that when p300 collaborates with p53 in p21 transcription.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

p21^waf1/cip1 (p21)¹ is a gene functioning as a cell cycle blocker, and its expression is usually regulated at transcription level. p21 was first cloned and characterized as an important effector that acts to inhibit cyclin-dependent kinase activity in p53-mediated cell cycle arrest induced by DNA damage (1-4). Further studies indicated that p21 is also regulated by other transcription factors during cell differentiation and growth arrest (5-8). During the study of cellular senescence, we found that the inhibitors of histone deacetylase, either sodium butyrate or TSA, can promote p21 transcription and induce growth arrest and senescence-like state in NIH 3T3 cells (9).² The minimal region of the mouse p21 promoter, containing from 60 to +40 bp relative to the TATA box, is essential and sufficient for the induction of p21 promoter by TSA. We reported also that a GC-box in this region is critical for both basal and TSA-induced promoter activity and that Sp1 and Sp3 are the functional activators of this GC-box (10). However, one question remained, how does histone acetylation affect Sp1-mediated transcription?

Recently, the study of transcriptional regulation has been moving its focus to chromatin level. The molecules involved in chromatin transcription include DNA (promoter, enhancer, or silencer), histones, and non-histone proteins. It has become increasingly apparent that the equilibrium of histone acetylation and deacetylation plays an important role in transcriptional regulation (11, 12). Several mammalian histone acetyltransferases and histone deacetylases have been cloned in recent years (13-19). p300 was first cloned as an E1A associated protein with properties of a transcriptional adapter (20). This protein was found later to possess intrinsic histone acetyltransferase activity and works as a coactivator in MyoD-, p53-, and SRC-1-mediated transcription (21-23). Indirect evidence has implicated p300 in cell cycle control and differentiation (24, 25). Although p300 has been found to be required for induction of p21 expression in keratinocyte differentiation (26), the cis-element in the p21 promoter and the sequence-specific transcriptional activator remained unknown.

The present work is part of our effort to understand the linkage between histone acetylation and Sp1-mediated transcription. Here we show evidence that p300 is required for TSA-induced, Sp1-mediated p21 transcription and discuss the possible mechanism of the functional interaction between Sp1 and p300 in p21 transcriptional activation.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Cells and Reagents-- HeLa cells from ATCC and COS-1 cells from RIKEN (Wako, Japan) were cultured in a 37 °C humidified atmosphere containing 5% CO₂ in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Trichostatin A (Wako, Osaka) was dissolved with ethanol at a concentration of 1 mg/ml and stored at 20 °C. The working solution was diluted with distilled phosphate-buffered saline to 10 µg/ml concentration and stored at 4 °C for less than 1 week.

Plasmid Constructs-- The full-length (pGL3b-4542), the wild type minimal region (pGL3b-60 or pRL-60), and the GC-box mutated minimal region (pGL3b-#4 or pRL-#4) of the p21 promoter inserted in two types of luciferase reporter containing vectors have been described elsewhere (10).

All expression vectors employed in this study were driven by the CMV promoter. Sp1 cDNA expressing constructs (pCGN-Sp1) and its backbone vector pCGN were kind gifts from Thomas Shenk (Princeton University) (27). Sp3 cDNA expressing construct (pCGN-Sp3) was generated by subcloning human Sp3 cDNA from pCMV4-Sp3flu into pCGN vector (10). p300 cDNA expressing construct(pGAL4p300) and its dominant-negative mutant (pGAL4p300/1514-1922) were provided by Antonio Giordano (Thomas Jefferson University) (28). pCAF cDNA expression vector (pCI-pCAF) was from Yoshihiro Nakatani (National Institutes of Health) (16). The Sp1 expression construct used for in vitro transcription and translation experiments was made by introducing the 2.0-kilobase XbaI/SmaI fragment of pERV2/Sp1 (21) into a T7 promoter containing expression vector, pcDNA3.1/Myc.HisC (Invitrogen), at XbaI and EcoRV sites. pRL-TK (Promega), a Renilla luciferase reporter vector, was used for transfection efficiency control. For mammalian two-hybrid experiments, the following constructs were used. 1) pG5luc was a 5-GAL4 DNA binding sites-containing firefly luciferase vector (Promega). 2) pGAL4p300 was the same construct as mentioned above, which is a chimeric fusion of GAL4 DNA binding domain (DBD) and full-length p300 cDNA. 3) pVP16pCAF was created by inserting the EagI/KpnI fragment of pCAF cDNA from pCI-pCAF into pACT vector (Promega), which has a VP16 activation domain (AD) sequence, at NotI and KpnI sites. 4) pVP16Sp1N was made by two steps. The 1.5-kilobase BamHI fragment of Sp1 cDNA from pCGN-Sp1 was inserted into pcDNA3.1/Myc.HisC vector at the BamHI site first, and then the EcoRV and KpnI insert from correctly directed clone was subcloned into pACT vector at the EcoRV and KpnI sites. 5) pVP16Sp1C was made by the same strategy as that for pVP16Sp1N except the 0.5-kilobase BamHI fragment of Sp1 cDNA was used, and 6) pRL-TK as mentioned above.

Transfection and Luciferase Assay-- Cells were seeded into 48-well plate at a density of 30,000 cells/well the day before transfection. In the transfection experiments with reporter plasmid only, HeLa cells were transfected with 100 ng of promoter-reporter construct by standard calcium phosphate procedure. Treatments of TSA were started after 24 h and continued for another 24 h generally, except where noted in the figure legends. In cDNA cotransfection experiments, transfection was performed by using Fugene^TM6 (Roche Molecular Biochemicals). The DNA mixture contained 20 ng of reporter and 20-100 ng of cDNA and either pCGN or pcDNA3.1 to adjust a total amount of DNA to 120 ng per well. For mammalian two-hybrid assays, COS-1 cells were transfected by standard calcium phosphate procedure with the combination of pG5luc, pGAL4, and pVP16 (or their corresponding fusions) in 1:1:1 molar ratio. pGEM-5Zf(+) vector was also added as carrier and for making the concentration of DNA to 0.3 µg/well. In all of these experiments, after 2 days of transfection, 5 of 50 µl of total cell lysate was used, and its luciferase activity was assayed by luminometer and dual luciferase assay kit (Promega). The luciferase activities were normalized against the activity of pRL-TK control vector (Promega) and protein concentration. Every experiment was performed at least three times.

Immunoprecipitation Pull-down Assays-- Labeled proteins were produced from pGAL4p300, pCI-pCAF, and pcDNA3.1/Myc.HisCSp1 plasmids by in vitro transcription and translation system (TNT kit, Promega) in the presence of [³⁵S]methionine. Two µl of in vitro translated ³⁵S protein and 2 µg of specific antibody were incubated in 50 µl of binding buffer (25 mM Tris-HCl (pH 8.0), 10% glycerol, 75 mM KCl, 5 mM MgCl₂, 0.1 mM EDTA, 0.1% Nonidet P-40, 1 mM dithiothreitol, 0.5 mM PMSF) at 4 °C for 1 h and with 10 µl of 3% bovine serum albumin-blocked protein G-Sepharose (Amersham Pharmacia Biotech, 50% slurry) for an additional 1 h. After washing with binding buffer three times, the beads were resuspended in 50 µl of the same buffer and incubated with 2 µl of labeled pCAF or Sp1 reaction mixture at room temperature for 30 min. Then the beads were washed again and boiled for 2 min in the presence of 20 µl of Laemmli buffer. Finally, the supernatants were separated on 8% SDS-polyacrylamide electrophoresis gel. For the immunoprecipitation of unlabeled cellular p300 protein, HeLa cell lysates in radioimmune precipitation buffer (25 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 2.5 mM EDTA, 1 mM dithiothreitol, 0.5 mM PMSF) were immunoprecipitated with anti-p300 antibody and protein G-Sepharose. The beads were washed by radioimmune precipitation buffer three times and binding buffer once. Thereafter, the beads were used for pull-down assay as described above.

Electrophoretic Mobility Shift Assay-- The experimental procedure was the same as that described previously (10) except that the nuclear extract was from HeLa cells, and only the ³²P-labeled oligonucleotides probe with the wild type p21 promoter sequence (40 to 10 bp from TATA box) was used. The polyclonal antibodies directed against Sp1 (catalogue number sc-59), Sp3 (sc-644), p300 N-terminal (p300-N, sc-584), p300 C-terminal (p300-C, sc-585) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The monoclonal antibody for p300 (p300-mono, 05-267) was from Upstate Biotechnology (Lake Placid, NY).

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Sp1/Sp3 Up-regulate p21 Promoter Activity through a TSA-responsive GC-box-- We have reported that TSA greatly induced the p21 promoter activity and determined the cis-element responsive to TSA in NIH 3T3 cells (10). We found that these results are not cellular-specific. In HeLa cells, the morphological differentiation and elevated p21 expression were also noticed after TSA treatment, and the minimal promoter region and TSA-responsive GC-box were the same as those in NIH 3T3 cells (results not shown). To confirm the functional effects of Sp1 family transcription factors on p21 promoter, especially on the TSA response of this promoter, we cotransfected wild type or the TSA-responsive GC-box-mutated promoter-luciferase constructs with Sp1 or Sp3 cDNA expression construct into HeLa cells (Fig. 1). While Sp1 and Sp3 can obviously activate wild type minimal promoter (pRL21-60) in a dose-dependent manner, they poorly activate the GC-box mutated minimal promoter (pRL21-#4) and empty vector (pRL-null). These results suggest that both Sp1 and Sp3 are the transactivators of the p21 promoter in HeLa cells, and they function through the TSA-responsive GC-box in vivo. Therefore, TSA, GC-box, and Sp1/Sp3 are tightly interrelated in p21 promoter activity.

View larger version (24K): [in this window] [in a new window]   Fig. 1.   Activation of p21 promoter by Sp1 and Sp3 is dependent on the GC-box response to TSA. Indicated amounts of Sp1 or Sp3 cDNA expression constructs were cotransfected with wild type p21 minimal promoter (pRL21-60), GC-box lost mutant (pRL21-#4), and their parent vector (pRL-null), respectively. Relative luciferase activity was derived from comparing the activities in the presence of Sp1 or Sp3 expression construct with the activity in the presence of the same amount of parental vector DNA. Values come from one of five separate experiments and represent the average of three samples with standard deviation.

p300 Participates in TSA-induced p21 Promoter Activation-- Because no changes in Sp1/Sp3 protein expression or in their DNA binding activity were found after TSA treatment (data not shown), we considered that TSA-induced p21 promoter activity may result from some kinds of interaction between Sp1/Sp3 and histone acetyltransferase or deacetylase. As the first step to issue this question, we examined the effect of p300 on p21 promoter. As shown in Fig. 2, transfection of wild type p300 expression construct, pGAL4p300, into cells enhanced either full-length (pGL3b-4542) or minimal promoter (pGL3b-60) activity. The experiments performed using the intact wild-type p300 (pCMVp300 provided from Prof. David M. Livingston) gave results similar to those using the GAL4 derivative (data not shown).This suggested the positive effect of p300 on p21 transcription. Different from p21 wild type minimal promoter, the activity of the GC-box mutated promoter (pGL3b-#4) was not affected by p300 cotransfection. Thus the TSA-responsive GC-box is also required for the function of p300 to the p21 promoter, as it is required for the function of Sp1/Sp3 on p21 promoter.

View larger version (27K): [in this window] [in a new window]   Fig. 2.   p300 activates full-length and minimal p21 promoter and its dependence on the TSA-responsive GC box. Indicated amounts of p300 cDNA expression construct (pGAL4p300) were cotransfected with full-length p21 promoter (pGL3b-4542), minimal p21 promoter (pGL3b-60), GC-box-mutated minimal p21 promoter (pGL3b-#4), or empty vector (pGL3b), respectively. Luciferase activity is the average of five samples. The results shown are from four separate experiments.

The interrelationship of p300 and TSA-induced promoter activation was further evidenced by cotransfection of a dominant-negative mutant of p300 expression construct (pGAL4p300/1514-1922) with p21 promoter construct, followed by TSA treatment. The product of pGAL4p300/1514-1922 encodes only a small portion of p300 protein, corresponding to the CH3 domain and its surroundings, and has been reported to be capable of interfering with the activity of endogenous protein (28, 30). In our experiment, this mutant lost the up-regulating effect of wild type p300 on the p21 promoter (Fig. 3A). Meanwhile, in the cells expressing this mutant p300, the p21 minimal promoter activity induced by TSA was obviously dose-dependent suppressed (Fig. 3B). These results suggest that the p300 molecule is also involved in TSA-induced p21 promoter activation.

View larger version (19K): [in this window] [in a new window]   Fig. 3.   Dominant-negative p300 blocks TSA-induced p21 activation. A, p300/1514-1922 functions as a dominant negative mutant for p21 transcription in HeLa cells. Indicated amounts of pGAL4p300 or pGAL4p300/1514-1922 were cotransfected with p21 promoter pGL3b-60. () refers to the control cotransfected with pcDNA3.1, which is the parental vector of pGAL4p300 and pGAL4p300/1514-1922, and pGL3b-60. B, cells were transfected with 50 ng/well pGL3b-60 and different amounts of pGAL4p300/1514-1922, followed by 24-h TSA treatment. Values represent the average of five samples and standard deviation. Three separate experiments were performed.

p300 Is Required for Sp1- or Sp3-mediated Transactivation of p21 Promoter-- Considering the facts that both Sp1/Sp3 and p300 can up-regulate p21 promoter and function through the same GC-box in TSA-induced p21 promoter activation, the cooperative relationship between them might be present. To expose the interrelationship of Sp1/Sp3 and p300, we investigated the requirement of p300 for Sp1/Sp3-mediated transactivation. When Sp1 or Sp3 was cotransfected with various amounts of dominant negative mutant p300, Sp1/Sp3-mediated promoter activation was dose-dependent blocked (Fig. 4). This result suggests that p300 is required for Sp1/Sp3-mediated p21 transcription and that some kind of collaboration between p300 and Sp1/Sp3 was present during this process.

View larger version (33K): [in this window] [in a new window]   Fig. 4.   Dominant-negative p300 suppresses Sp1/Sp3-mediated p21 activation. Various amounts of pGAL4p300/1514-1922 were introduced into cells with pCGN-Sp1 or pCGN-Sp3, as well as p21 promoter. Relative luciferase activity of cell lysate was measured after 48 h. Values represent the average of five samples and standard deviation. Three separate experiments were performed.

p300 Does Not Directly Interact with Sp1 in Vitro and in Vivo-- The cooperation of p300 and Sp1/Sp3 shown in functional assays described above may be from direct or indirect interaction of p300 with Sp1/Sp3. As p300 has been shown to physically interact with various transcription factors, we examined the physical relationship between p300 and Sp1 in vitro and in vivo. Fig. 5 showed the results from two kinds of in vitro protein binding assays. In immunoprecipitation pull-down assay (Fig. 5A), the positive control, recombinant pCAF protein, can associate with recombinant p300 (lane 4) or native p300 (lane 7), whereas recombinant Sp1 cannot (lanes 5 and 8). That Sp1 does not associate with p300 in vitro was also implied from super shift assay (Fig. 5B). In this experiment, three kinds of antibodies for p300 failed to produce any shift or the loss of Sp1 and Sp3 complexes which were binding to the TSA-responsive GC-box-containing oligonucleotides (lanes 4-6). To examine whether there is the physical interaction between p300 and Sp1 in cellular situation, mammalian two-hybrid assay was performed. Fig. 6A shows the structures of fusion proteins produced in transfected cells and the schematic representation of this two-hybrid system. Briefly, after cotransfecting the GAL4 binding sites-containing reporter construct with GAL4DBD-fused vector as well as VP16AD-fused vector, the luciferase activity induced was detected. As shown in Fig. 6B, when the GAL4DBD-fused p300 protein expressed together with the VP16AD-fused pCAF protein, which is a known p300 association protein, the luciferase activity in cells increased more than 2-fold. However, when the GAL4DBD-fused p300 expressed with VP16AD-fused Sp1, neither its N-terminal nor C-terminal portion, the luciferase activity was not affected compared with that with VP16AD only. This means that the exogenous p300 and Sp1 did not interact directly in this system. In vivo co-immunoprecipitation was also tried to detect the interaction of endogenous p300 and Sp1, but no positive clue was found (data not shown).

View larger version (54K): [in this window] [in a new window]   Fig. 5.   p300 does not directly interact with Sp1 in vitro. A, immunoprecipitation pull-down assays. [35S]methionine-labeled p300, pCAF, and Sp1 were made by in vitro transcription/translation (lanes 1-8), whereas cold p300 was from unlabeled HeLa cells (lanes 7 and 8). 10% of individual 35S-protein was directly loaded on gel and referred to as input (lanes 1-3). For immunoprecipitation, 35S-p300 (lanes 4 and 5), 35S-Sp1 (lane 6), or cold native p300 (lanes 7 and 8) were precipitated from in vitro translation mixture or cell lysate by specific antibodies and then mixed with 35S-pCAF (lanes 4 and 7), 35S-Sp1 (lanes 5 and 8), and 35S-p300 (lane 6), respectively. After binding incubation, the beads were washed and the precipitated proteins were separated by 8% SDS-polyacrylamide gel electrophoresis gel. B, super-shift assay. 32P-labeled double-stranded oligonucleotides with the TSA-responsive GC-box-containing sequence of the p21 promoter, HeLa cell nuclear extracts, and indicated antibodies were incubated together, and the reaction mixtures were loaded on 4% acrylamide gel and separated. The antibodies used were: anti-Sp1 (lane 2), anti-Sp3 (lane 3), anti-p300(N) (lane 4), anti-p300 (C) (lane 5), and anti-p300(mono) (lane 6).

View larger version (24K): [in this window] [in a new window]   Fig. 6.   p300 does not directly interact with Sp1 in mammalian two-hybrid system. A, schematic representation of the two-hybrid system. The full-length p300 was cloned into a GAL4DBD-containing vector; the almost full-length of pCAF or indicated regions of Sp1 were inserted into a VP16AD-containing vector. Both of them were cotransfected with a GAL4 DNA binding sites-containing luciferase reporter vector. B, luciferase activity induced by different combinations of cotransfection. COS-1 cells seeded in a 48-well plate were transfected with the DNA mixture composed of the same molar ratio of pG5luc, GAL4p300, and VP16pCAF, VP16Sp1N, or VP16Sp1C. 30 ng of pRL-TK and a different amount of pGEM-5Zf(+) were used as internal control and carrier DNA, respectively. The total amount of DNA is 0.3 µg/well. Every point was triplicate, and the data are representative of three experiments. +, present; , absent.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The original purpose of this work is to elucidate how TSA affected Sp1-mediated p21 transcription. In view of recent progress in transcriptional regulation, we assumed that some kinds of histone acetyltransferase and/or deacetylase may be altered physically or functionally during TSA treatment and thus influence function of Sp1 family transcription factors. In working to try to identify these involved histone acetyltransferase and/or deacetylase, we found that p300, one of the histone acetyltransferases, up-regulates p21 promoter and functions through the GC-box responsible to TSA (Figs. 2 and 3). The dominant negative mutant of p300 can clearly block TSA-induced p21 activation, further supporting the opinion that p300 functionally contributes to TSA-induced p21 activation.

It has been reported that p300 works as a coactivator for various transcription activators, such as MyoD, p53, RAR, CREB, c-Jun, and for basal transcription factors, for example TBP (21-23). There is no report up to now implying the interaction of p300 and Sp1 family transcription factors. The same GC-box dependence of Sp1/Sp3 and p300 in p21 promoter activation reported in our present work, thereby, raises the possibility that p300 may cooperate with Sp1 family transcription factors as well.

To address this question, the dominant negative mutant of p300 was cotransfected with Sp1 or Sp3 based on the idea that if the cooperative relationship is present, cellular knockout of p300 will abolish the function of Sp1/Sp3. Our results support this idea (Figs. 3 and 4). Owen, et al. (31) reported recently that progesterone regulates transcription of p21 gene through Sp1 and CBP/p300. They showed data indicating that progesterone regulates p21 promoter activity through a Sp1 site and E1A can abolish the effect of progesterone on p21 promoter containing this Sp1 site. Given that other proteins except CBP/p300 also associate with E1A (32-34), we think the result from cotransfecting with E1A may not be enough for supporting the involvement of p300 in this Sp1 site-mediated transcription. By comparing the different effect of p300 on wild type or GC-box-mutated promoter and utilizing its dominant negative mutant to suppress TSA- and Sp1/Sp3-induced transactivation, we provide direct evidence here that p300 can regulate the activity of the p21 promoter through Sp1-mediated transcription.

p300 is also involved in p21 transcription through a p53-mediated way (22, 30). In that case, p300 physically interacts with p53 and is recruited by p53 to the basal transcription machinery. However, the molecular basis of the collaboration of p300 and Sp1 in p21 promoter regulation seems different. As the results from in vitro and in vivo experiments failed to provide any evidence that p300 directly interact with Sp1 (Figs. 5, 6), we considered that p300 and Sp1 might indirectly interact through a common multi-protein complex which is important for p21 transcription. Given that either p300 or Sp1 can interact with TBP and other basal transcription factors (35-37), and that the Sp1 binding site in p21 promoter is so close to TATA box, this multi-protein complex might be the transcription initiation complex. Thus, we propose one hypothesis here, that the functional collaboration of p300 and Sp1 in p21 expression may rely on the effect of p300 on the activity of the initiation complex or the interaction of this complex with Sp1, which is the base for Sp1-mediated transcription in p21 activation. In fact, a multi-protein transcriptional complex containing TATA-binding protein, Sp1, and cAMP-response element-binding protein (CBP/p300) has been noticed recently (29). We prefer to say, based on the results presented here, that p300 is an indispensable factor for the p21 promoter activation, not only in a p53-mediated, DNA damage-responsible way but also in Sp1-mediated, basal and histone acetylation-effected way. Further work remains to be done to identify more details about the cooperation of p300 and Sp1.

	ACKNOWLEDGEMENTS

We thank Prof. Jonathan M. Horowitz (University of North Carolina), Prof. Thomas Shenk (Princeton University), Prof. Antonio Giordano (Thomas Jefferson University), Prof. David M. Livingston (Dana-Faber Cancer Institute), and Prof. Yoshihiro Nakatani (National Institutes of Health) for providing plasmids.

	FOOTNOTES

^* This study was supported by the Fund for Comprehensive Research on Aging and Health and that for Longevity Sciences (101-03) from the Ministry of Health and Welfare of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^¶ Present address: Laboratory for Genes of Motor Systems, Bio-mimetic Control Res., RIKEN.

To whom correspondence should be addressed. Tel.: 81-562-46-2311; Fax: 81-562-44-6591; E-mail: kenisobe@nils.go.jp.

² H. Xiao, T. Hasegawa, and K-i. Isobe, unpublished data.

	ABBREVIATIONS

The abbreviations used are: p21, p21^waf1/cip1; TSA, trichostatin A; DBD, DNA binding domain; AD, activation domain; bp, base pair; PMSF, phenylmethylsulfonyl fluoride.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				H. Nian, B. Delage, J. T. Pinto, and R. H. Dashwood Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter Carcinogenesis, September 1, 2008; 29(9): 1816 - 1824. [Abstract] [Full Text] [PDF]

				V. Bartella, S. Cascio, E. Fiorio, A. Auriemma, A. Russo, and E. Surmacz Insulin-Dependent Leptin Expression in Breast Cancer Cells Cancer Res., June 15, 2008; 68(12): 4919 - 4927. [Abstract] [Full Text] [PDF]

				M. Yoshida, Y. Kabe, T. Wada, A. Asai, and H. Handa A New Mechanism of 6-((2-(Dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one Dihydrochloride (TAS-103) Action Discovered by Target Screening with Drug-Immobilized Affinity Beads Mol. Pharmacol., March 1, 2008; 73(3): 987 - 994. [Abstract] [Full Text] [PDF]

				J.-Y. Chuang, Y.-T. Wang, S.-H. Yeh, Y.-W. Liu, W.-C. Chang, and J.-J. Hung Phosphorylation by c-Jun NH2-terminal Kinase 1 Regulates the Stability of Transcription Factor Sp1 during Mitosis Mol. Biol. Cell, March 1, 2008; 19(3): 1139 - 1151. [Abstract] [Full Text] [PDF]

				J. Fan, J. Stanfield, Y. Guo, J. A. Karam, E. Frenkel, X. Sun, and J.-T. Hsieh Effect of Trans-2,3-Dimethoxycinnamoyl Azide on Enhancing Antitumor Activity of Romidepsin on Human Bladder Cancer Clin. Cancer Res., February 15, 2008; 14(4): 1200 - 1207. [Abstract] [Full Text] [PDF]

				L. Andresen, H. Jensen, M. T. Pedersen, K. A. Hansen, and S. Skov Molecular Regulation of MHC Class I Chain-Related Protein A Expression after HDAC-Inhibitor Treatment of Jurkat T Cells J. Immunol., December 15, 2007; 179(12): 8235 - 8242. [Abstract] [Full Text] [PDF]

				Y.-J. Chen, Y.-N. Wang, and W.-C. Chang ERK2-mediated C-terminal Serine Phosphorylation of p300 Is Vital to the Regulation of Epidermal Growth Factor-induced Keratin 16 Gene Expression J. Biol. Chem., September 14, 2007; 282(37): 27215 - 27228. [Abstract] [Full Text] [PDF]

				M. De los Santos, A. Zambrano, and A. Aranda Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells Mol. Cancer Ther., April 1, 2007; 6(4): 1425 - 1432. [Abstract] [Full Text] [PDF]

				F. Liu, N. Pore, M. Kim, K. R. Voong, M. Dowling, A. Maity, and G. D. Kao Regulation of Histone Deacetylase 4 Expression by the SP Family of Transcription Factors Mol. Biol. Cell, February 1, 2006; 17(2): 585 - 597. [Abstract] [Full Text] [PDF]

				I. Hoshino, H. Matsubara, N. Hanari, M. Mori, T. Nishimori, Y. Yoneyama, Y. Akutsu, H. Sakata, K. Matsushita, N. Seki, et al. Histone Deacetylase Inhibitor FK228 Activates Tumor Suppressor Prdx1 with Apoptosis Induction in Esophageal Cancer Cells Clin. Cancer Res., November 1, 2005; 11(21): 7945 - 7952. [Abstract] [Full Text] [PDF]

				J.-J. Hung, C.-Y. Wu, P.-C. Liao, and W.-C. Chang Hsp90{alpha} Recruited by Sp1 Is Important for Transcription of 12(S)-Lipoxygenase in A431 Cells J. Biol. Chem., October 28, 2005; 280(43): 36283 - 36292. [Abstract] [Full Text] [PDF]

				M. Sakaguchi, H. Sonegawa, T. Nukui, Y. Sakaguchi, M. Miyazaki, M. Namba, and N.-h. Huh Bifurcated converging pathways for high Ca2+- and TGF{beta}-induced inhibition of growth of normal human keratinocytes PNAS, September 27, 2005; 102(39): 13921 - 13926. [Abstract] [Full Text] [PDF]

				M. V. Blagosklonny, S. Trostel, G. Kayastha, Z. N. Demidenko, L. T. Vassilev, L. Y. Romanova, S. Bates, and T. Fojo Depletion of Mutant p53 and Cytotoxicity of Histone Deacetylase Inhibitors Cancer Res., August 15, 2005; 65(16): 7386 - 7392. [Abstract] [Full Text] [PDF]

				E. M. Ongeri, M. F. Verderame, and J. M. Hammond Follicle-Stimulating Hormone Induction of Ovarian Insulin-Like Growth Factor-Binding Protein-3 Transcription Requires a TATA Box-Binding Protein and the Protein Kinase A and Phosphatidylinositol-3 Kinase Pathways Mol. Endocrinol., July 1, 2005; 19(7): 1837 - 1848. [Abstract] [Full Text] [PDF]

				J.-P. Brouland, P. Gelebart, T. Kovacs, J. Enouf, J. Grossmann, and B. Papp The Loss of Sarco/Endoplasmic Reticulum Calcium Transport ATPase 3 Expression Is an Early Event during the Multistep Process of Colon Carcinogenesis Am. J. Pathol., July 1, 2005; 167(1): 233 - 242. [Abstract] [Full Text] [PDF]

				W. Huang, S. Zhao, S. Ammanamanchi, M. Brattain, K. Venkatasubbarao, and J. W. Freeman Trichostatin A Induces Transforming Growth Factor {beta} Type II Receptor Promoter Activity and Acetylation of Sp1 by Recruitment of PCAF/p300 to a Sp1{middle dot}NF-Y Complex J. Biol. Chem., March 18, 2005; 280(11): 10047 - 10054. [Abstract] [Full Text] [PDF]

				R. Varshochi, F. Halim, A. Sunters, J. P. Alao, P. A. Madureira, S. M. Hart, S. Ali, D. M. Vigushin, R. C. Coombes, and E. W.-F. Lam ICI182,780 Induces p21Waf1 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor {alpha} from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line J. Biol. Chem., February 4, 2005; 280(5): 3185 - 3196. [Abstract] [Full Text] [PDF]

				T. Torigoe, H. Izumi, T. Wakasugi, I. Niina, T. Igarashi, T. Yoshida, I. Shibuya, K. Chijiiwa, K.-i. Matsuo, H. Itoh, et al. DNA Topoisomerase II Poison TAS-103 Transactivates GC-Box-dependent Transcription via Acetylation of Sp1 J. Biol. Chem., January 14, 2005; 280(2): 1179 - 1185. [Abstract] [Full Text] [PDF]

				G. Tsika, J. Ji, and R. Tsika Sp3 Proteins Negatively Regulate {beta} Myosin Heavy Chain Gene Expression during Skeletal Muscle Inactivity Mol. Cell. Biol., December 15, 2004; 24(24): 10777 - 10791. [Abstract] [Full Text] [PDF]

				J. Hong, I. Samudio, S. Liu, M. Abdelrahim, and S. Safe Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Activation of p21 in Panc-28 Pancreatic Cancer Cells Involves Sp1 and Sp4 Proteins Endocrinology, December 1, 2004; 145(12): 5774 - 5785. [Abstract] [Full Text] [PDF]